Arcturus Therapeutics
ARCT
50 hedge funds and large institutions have $50.1M invested in Arcturus Therapeutics in 2019 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 18 increasing their positions, 7 reducing their positions, and 6 closing their positions.
157% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 7
133% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 6
19% more funds holding
Funds holding: 42 → 50 (+8)
6% more capital invested
Capital invested by funds: $47.3M → $50.1M (+$2.75M)
2.24% less ownership
Funds ownership: 32.32% → 30.08% (-2.2%)
47% less call options, than puts
Call options by funds: $458K | Put options by funds: $871K
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$1.14M |
| 2 |
Morgan Stanley
New York
|
+$834K |
| 3 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$709K |
| 4 |
Two Sigma Investments
New York
|
+$637K |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$618K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TC
TownSquare Capital
Provo,
Utah
|
-$4.54M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1.28M |
| 3 |
HCM
Highline Capital Management
New York
|
-$607K |
| 4 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$227K |
| 5 |
NAMA
Nikko Asset Management Americas
New York
|
-$188K |
ARCT Hedge Fund Activity: Q4 2019 in Review
50 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Arcturus Therapeutics (ARCT) for Q4 2019, worth a combined $50.1M — up 5.8% from $47.3M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new ARCT positions and 6 closed out — a net gain of 8 holders — while 18 added to existing stakes and 7 trimmed.
The largest buyer was ARK Investment Management, adding an estimated $1.14M. The largest seller was TownSquare Capital, exiting entirely with an estimated $4.54M sold.
- 50 institutional investors held Arcturus Therapeutics (ARCT) as of Q4 2019, up from 42 in Q3 2019.
- Funds reported $50.1M of Arcturus Therapeutics stock for Q4 2019, up 5.8% quarter-over-quarter.
- 14 funds opened new Arcturus Therapeutics positions in Q4 2019 and 6 closed out, a net change of +8 holders.
- The largest Arcturus Therapeutics buyer in Q4 2019 was ARK Investment Management, an estimated $1.14M added.
- The largest Arcturus Therapeutics seller in Q4 2019 was TownSquare Capital, an estimated $4.54M sold.
Based on aggregated 13F filings for Q4 2019.